Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Frost

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Urology|March 7, 2017
Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related AngiomyolipomasElyse Swallow, Sarah King, Jinlin Song, et al.
The American Journal of Surgical Pathology|June 27, 2003
BCL-2 is consistently expressed in hyperplastic marginal zones of the spleen, abdominal lymph nodes, and ileal lymphoid tissueBrenton A Meda, Michael Frost, James Newell, et al.
Journal of Addiction Medicine|April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical TrialMichelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.
BMC Medical Informatics and Decision Making|January 8, 2020
Development of a targeted client communication intervention to women using an electronic maternal and child health registry: a qualitative studyBinyam Bogale, Kjersti Mørkrid, Brian O'Donnell, et al.
Lancet (London, England)|July 6, 2021
Development of a targeted client communication intervention for pregnant and post-partum women: a descriptive studyBinyam Bogale, Kjersti Mørkrid, Brian O'Donnell, et al.
Addiction (Abingdon, England)|April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorderMichael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Epilepsia|December 5, 2008
Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsyJames W Wheless, Lionel Carmant, Martina Bebin, et al.
JAMA Internal Medicine|May 26, 2018
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical TrialMichelle R Lofwall, Sharon L Walsh, Edward V Nunes, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2015
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trialJohn J Bissler, John Christopher Kingswood, Elżbieta Radzikowska, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Urology|March 7, 2017
Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related AngiomyolipomasElyse Swallow, Sarah King, Jinlin Song, et al.
The American Journal of Surgical Pathology|June 27, 2003
BCL-2 is consistently expressed in hyperplastic marginal zones of the spleen, abdominal lymph nodes, and ileal lymphoid tissueBrenton A Meda, Michael Frost, James Newell, et al.
Journal of Addiction Medicine|April 7, 2025
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical TrialMichelle R Lofwall, Edward V Nunes, Sharon L Walsh, et al.
BMC Medical Informatics and Decision Making|January 8, 2020
Development of a targeted client communication intervention to women using an electronic maternal and child health registry: a qualitative studyBinyam Bogale, Kjersti Mørkrid, Brian O'Donnell, et al.
Lancet (London, England)|July 6, 2021
Development of a targeted client communication intervention for pregnant and post-partum women: a descriptive studyBinyam Bogale, Kjersti Mørkrid, Brian O'Donnell, et al.
Addiction (Abingdon, England)|April 24, 2019
Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorderMichael Frost, Genie L Bailey, Nicholas Lintzeris, et al.
Epilepsia|December 5, 2008
Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsyJames W Wheless, Lionel Carmant, Martina Bebin, et al.
JAMA Internal Medicine|May 26, 2018
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical TrialMichelle R Lofwall, Sharon L Walsh, Edward V Nunes, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2015
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trialJohn J Bissler, John Christopher Kingswood, Elżbieta Radzikowska, et al.
The Lancet. Oncology|December 3, 2014
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 studyDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Pageof 4